Litcius/Paper detail

Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece

George Gourzoulidis, C. Tzanetakos, Ioannis Ioannidis, Vasilis Tsimihodimos, Viana Diogo, George Karpouzos, Giannis Papageorgiou, Georgia Kourlaba

2021Clinical Drug Investigation10 citationsDOI

Topics & Concepts

DapagliflozinEmpagliflozinMedicinePharmacotherapyDiabetes mellitusDiseaseType 2 Diabetes MellitusIntensive care medicineType 2 diabetesBenzhydryl compoundsInternal medicineEndocrinologyEpoxyChemistryBisphenol AOrganic chemistryDiabetes Treatment and ManagementDiabetes Management and ResearchHyperglycemia and glycemic control in critically ill and hospitalized patients
Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece | Litcius